Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $8.30 Consensus Target Price from Brokerages

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $8.30.

Several research firms have recently weighed in on CGTX. B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $1.00 to $1.50 in a report on Thursday, December 19th. Chardan Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a research report on Thursday, December 19th. Finally, HC Wainwright raised their price objective on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th.

Cognition Therapeutics Stock Down 1.8 %

Shares of NASDAQ CGTX opened at $0.68 on Friday. The business has a 50-day moving average price of $0.57 and a 200 day moving average price of $0.74. The stock has a market cap of $28.33 million, a PE ratio of -0.70 and a beta of 0.95. Cognition Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.95.

Institutional Trading of Cognition Therapeutics

Several hedge funds have recently made changes to their positions in CGTX. SG Americas Securities LLC purchased a new stake in shares of Cognition Therapeutics in the fourth quarter valued at approximately $26,000. Virtu Financial LLC acquired a new stake in Cognition Therapeutics in the third quarter valued at $27,000. Sigma Planning Corp boosted its position in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its stake in shares of Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares during the period. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.